DV
Dividend Vision

PVLA — Palvella Therapeutics, Inc.

Palvella Therapeutics, Inc. (PVLA)

Total return is -29.0% over the past 11.6 years, 386.5 points behind SPY at 357.5%. Its deepest 1-year drawdown was 31.1%.

Palvella Therapeutics is a clinical-stage biopharmaceutical company developing novel topical therapies for rare genetic skin diseases, with its lead candidate QTORIN rapamycin currently in Phase 3 trials for microcystic lymphatic malformations and Phase 2 trials for cutaneous venous malformations. As an early-stage biotech company with no approved products, it does not currently distribute dividends. This security appeals to investors with higher risk tolerance seeking exposure to clinical-stage drug development rather than current income.

PVLA key facts

Asset type
Stock
Asset class
Equity
Inception date
01/02/2015
Distribution frequency
None
Last close
$156.13
Market cap
$2,249,584,640
Average volume
109800.0
Payout ratio
0.0
Forward P/E
0.0
EPS
$-4.85